Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Identifieur interne : 000843 ( PubMed/Corpus ); précédent : 000842; suivant : 000844Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Auteurs : Franck E. Nicolini ; Grzegorz W. Basak ; Dong-Wook Kim ; Eduardo Olavarria ; Javier Pinilla-Ibarz ; Jane F. Apperley ; Timothy Hughes ; Dietger Niederwieser ; Michael J. Mauro ; Charles Chuah ; Andreas Hochhaus ; Giovanni Martinelli ; Maral Dersarkissian ; Mei Sheng Duh ; Lisa J. Mcgarry ; Hagop M. Kantarjian ; Jorge E. CortesSource :
- Cancer [ 1097-0142 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (therapeutic use), Blast Crisis (genetics), Blast Crisis (therapy), Female, Humans, Imidazoles (therapeutic use), Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy), Male, Middle Aged, Multivariate Analysis, Mutation, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics), Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy), Proportional Hazards Models, Pyridazines (therapeutic use), Retrospective Studies, Stem Cell Transplantation (methods), Survival Rate, Transplantation, Homologous, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Imidazoles, Pyridazines.
- genetics : Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- methods : Stem Cell Transplantation.
- therapy : Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Mutation, Philadelphia Chromosome, Proportional Hazards Models, Retrospective Studies, Survival Rate, Transplantation, Homologous, Treatment Outcome.
Abstract
Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT).
DOI: 10.1002/cncr.30558
PubMed: 28387926
Links to Exploration step
pubmed:28387926Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.</title><author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name><affiliation><nlm:affiliation>Hematology Department, Lyon South-Pierre-Bénite Hospital Center and Unit 1052, National Institute of Health and Medical Research Lyon Cancer Research Center/Léon Berard Center, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Basak, Grzegorz W" sort="Basak, Grzegorz W" uniqKey="Basak G" first="Grzegorz W" last="Basak">Grzegorz W. Basak</name><affiliation><nlm:affiliation>Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name><affiliation><nlm:affiliation>Leukemia Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name><affiliation><nlm:affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Pinilla Ibarz, Javier" sort="Pinilla Ibarz, Javier" uniqKey="Pinilla Ibarz J" first="Javier" last="Pinilla-Ibarz">Javier Pinilla-Ibarz</name><affiliation><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F" last="Apperley">Jane F. Apperley</name><affiliation><nlm:affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name><affiliation><nlm:affiliation>Department of Pathology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:affiliation>Department of Haematology and Medical Oncology, University of Leipzig, Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mauro, Michael J" sort="Mauro, Michael J" uniqKey="Mauro M" first="Michael J" last="Mauro">Michael J. Mauro</name><affiliation><nlm:affiliation>Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name><affiliation><nlm:affiliation>Department of Haematology, Singapore General Hospital, Duke-NUS Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:affiliation>Clinic and Polyclinic for Internal Medicine II, Division of Hematology and Oncology, Jena University Hospital, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name><affiliation><nlm:affiliation>L. e A. Seragnoli Institute of Hematology, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dersarkissian, Maral" sort="Dersarkissian, Maral" uniqKey="Dersarkissian M" first="Maral" last="Dersarkissian">Maral Dersarkissian</name><affiliation><nlm:affiliation>Analysis Group, Inc, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Duh, Mei Sheng" sort="Duh, Mei Sheng" uniqKey="Duh M" first="Mei Sheng" last="Duh">Mei Sheng Duh</name><affiliation><nlm:affiliation>Analysis Group, Inc, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Mcgarry, Lisa J" sort="Mcgarry, Lisa J" uniqKey="Mcgarry L" first="Lisa J" last="Mcgarry">Lisa J. Mcgarry</name><affiliation><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E" last="Cortes">Jorge E. Cortes</name><affiliation><nlm:affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28387926</idno><idno type="pmid">28387926</idno><idno type="doi">10.1002/cncr.30558</idno><idno type="wicri:Area/PubMed/Corpus">000843</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000843</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.</title><author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name><affiliation><nlm:affiliation>Hematology Department, Lyon South-Pierre-Bénite Hospital Center and Unit 1052, National Institute of Health and Medical Research Lyon Cancer Research Center/Léon Berard Center, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Basak, Grzegorz W" sort="Basak, Grzegorz W" uniqKey="Basak G" first="Grzegorz W" last="Basak">Grzegorz W. Basak</name><affiliation><nlm:affiliation>Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name><affiliation><nlm:affiliation>Leukemia Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name><affiliation><nlm:affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Pinilla Ibarz, Javier" sort="Pinilla Ibarz, Javier" uniqKey="Pinilla Ibarz J" first="Javier" last="Pinilla-Ibarz">Javier Pinilla-Ibarz</name><affiliation><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F" last="Apperley">Jane F. Apperley</name><affiliation><nlm:affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name><affiliation><nlm:affiliation>Department of Pathology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:affiliation>Department of Haematology and Medical Oncology, University of Leipzig, Leipzig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mauro, Michael J" sort="Mauro, Michael J" uniqKey="Mauro M" first="Michael J" last="Mauro">Michael J. Mauro</name><affiliation><nlm:affiliation>Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name><affiliation><nlm:affiliation>Department of Haematology, Singapore General Hospital, Duke-NUS Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:affiliation>Clinic and Polyclinic for Internal Medicine II, Division of Hematology and Oncology, Jena University Hospital, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name><affiliation><nlm:affiliation>L. e A. Seragnoli Institute of Hematology, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dersarkissian, Maral" sort="Dersarkissian, Maral" uniqKey="Dersarkissian M" first="Maral" last="Dersarkissian">Maral Dersarkissian</name><affiliation><nlm:affiliation>Analysis Group, Inc, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Duh, Mei Sheng" sort="Duh, Mei Sheng" uniqKey="Duh M" first="Mei Sheng" last="Duh">Mei Sheng Duh</name><affiliation><nlm:affiliation>Analysis Group, Inc, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Mcgarry, Lisa J" sort="Mcgarry, Lisa J" uniqKey="Mcgarry L" first="Lisa J" last="Mcgarry">Lisa J. Mcgarry</name><affiliation><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author><author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E" last="Cortes">Jorge E. Cortes</name><affiliation><nlm:affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cancer</title><idno type="eISSN">1097-0142</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (therapeutic use)</term><term>Blast Crisis (genetics)</term><term>Blast Crisis (therapy)</term><term>Female</term><term>Humans</term><term>Imidazoles (therapeutic use)</term><term>Kaplan-Meier Estimate</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Mutation</term><term>Philadelphia Chromosome</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy)</term><term>Proportional Hazards Models</term><term>Pyridazines (therapeutic use)</term><term>Retrospective Studies</term><term>Stem Cell Transplantation (methods)</term><term>Survival Rate</term><term>Transplantation, Homologous</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Imidazoles</term><term>Pyridazines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Blast Crisis</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Stem Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Blast Crisis</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Mutation</term><term>Philadelphia Chromosome</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Transplantation, Homologous</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28387926</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>07</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0142</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>15</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.</ArticleTitle><Pagination><MedlinePgn>2875-2880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.30558</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A post hoc, retrospective, indirect comparison of OS among patients who received single-agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo-SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan-Meier survival curves and multivariate Cox proportional-hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24-month and 48-month OS rates and median OS were reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for potential confounders, 24-month and 48-month OS rates were significantly higher in patients with chronic-phase CML (CP-CML) who received ponatinib compared with those who underwent allo-SCT (24 months: 84% vs 60.5%, respectively; P = .004; 48 months: 72.7% vs 55.8%, respectively; P = .013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16-0.84; P = .017). In patients who had accelerated-phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20-4.10; P = .889). In patients who had blast-crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo-SCT (blast-crisis CML: HR, 2.29 [95% CI, 1.08-4.82; P = .030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73-10.56; P = .146]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I-positive CP-CML. Cancer 2017;123:2875-80. © 2017 American Cancer Society.</AbstractText><CopyrightInformation>© 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicolini</LastName><ForeName>Franck E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Hematology Department, Lyon South-Pierre-Bénite Hospital Center and Unit 1052, National Institute of Health and Medical Research Lyon Cancer Research Center/Léon Berard Center, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basak</LastName><ForeName>Grzegorz W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-Wook</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Leukemia Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olavarria</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinilla-Ibarz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apperley</LastName><ForeName>Jane F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niederwieser</LastName><ForeName>Dietger</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Haematology and Medical Oncology, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauro</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuah</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Haematology, Singapore General Hospital, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochhaus</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic and Polyclinic for Internal Medicine II, Division of Hematology and Oncology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>L. e A. Seragnoli Institute of Hematology, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DerSarkissian</LastName><ForeName>Maral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duh</LastName><ForeName>Mei Sheng</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGarry</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarjian</LastName><ForeName>Hagop M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>4340891KFS</RegistryNumber><NameOfSubstance UI="C545373">ponatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Biologics. 2014 Oct 20;8:243-54</RefSource><PMID Version="1">25349473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2005 Jun 1;65(11):4500-5</RefSource><PMID Version="1">15930265</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2015 May 15;121(10):1637-44</RefSource><PMID Version="1">25586015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2010 Nov 4;116(18):3409-17</RefSource><PMID Version="1">20656928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Nov 7;369(19):1783-96</RefSource><PMID Version="1">24180494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2010 Jan;95(1):8-12</RefSource><PMID Version="1">20065078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2016 Mar;30(3):562-9</RefSource><PMID Version="1">26464170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Nov 17;118(20):5697-700</RefSource><PMID Version="1">21926354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Nov;16(15):1547-55</RefSource><PMID Version="1">26432046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2009 Nov 6;16(5):401-12</RefSource><PMID Version="1">19878872</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Comput Methods Programs Biomed. 2004 Jul;75(1):45-9</RefSource><PMID Version="1">15158046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Dec 17;114(26):5271-8</RefSource><PMID Version="1">19843886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemiology. 2000 Sep;11(5):550-60</RefSource><PMID Version="1">10955408</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemiology. 2000 Sep;11(5):561-70</RefSource><PMID Version="1">10955409</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2013 Oct;98(10):1510-6</RefSource><PMID Version="1">23716543</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001752" MajorTopicYN="N">Blast Crisis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010677" MajorTopicYN="N">Philadelphia Chromosome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)</Keyword><Keyword MajorTopicYN="N">allogeneic stem cell transplantation (allo-SCT)</Keyword><Keyword MajorTopicYN="N">chronic myeloid leukemia (CML)</Keyword><Keyword MajorTopicYN="N">ponatinib</Keyword><Keyword MajorTopicYN="N">threonine to isoleucine mutation at codon 315 (T315I)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28387926</ArticleId><ArticleId IdType="doi">10.1002/cncr.30558</ArticleId><ArticleId IdType="pmc">PMC5573914</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000843 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000843 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28387926
|texte= Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28387926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |